Publikationen (seit 2007)

Heneka, M.T., Kummer, M.P., Weggen, S., Bulic, B., Multhaup, G., Munter, L., Hull, M., Pflanzner, T. & Pietrzik, C.U. (2011) "Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease" Curr. Alzheimer Res. 8, 115-131

Hahn, S., Bruning, T., Ness, J., Czirr, E., Baches, S., Gijsen, H., Korth, C., Pietrzik, C.U., Bulic, B. & Weggen, S. (2011) "Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to gamma-secretase modulators regardless of their potency and structure" J. Neurochem. 116, 385-395

Richter, L., Munter, L.M., Ness, J., Hildebrand, P.W., Dasari, M., Unterreitmeier, S., Bulic, B., Beyermann, M., Gust, R., Reif, B., Weggen, S., Langosch, D. & Multhaup, G. (2010) "Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization" PNAS 107, 14597-14602

Bulic, B., Pickhardt, M., Mandelkow, E.M. & Mandelkow, E. (2010) “Tau protein and tau aggregation inhibitors” Neuropharmacology 59, 276-289

Bulic, B. (2009) “Trapoxin B: From Total Synthesis to Epigenetics” In: Chemical Biology (Weinheim: Wiley-VCH),  135-144

Bulic B., Pickhardt, M., Schmidt, B., Mandelkow, E.M., Waldmann, H. & Mandelkow, E. (2009) “Development of Tau Aggregation Inhibitors for Alzheimer´s Disease” Angew. Chem. Int. Ed. 48, 1740-1752

Mishra, R., Bulic, B., Sellin, D., Jha, S., Waldmann, H. & Winter, R. (2008) “Small-molecule Inhibitors of Islet Amyloid Polypeptide Fibril Formation” Angew. Chem. Int. Ed. 47, 4679-4682

Bulic, B., Pickhardt, M., Khlistunova, I., Biernat, J., Mandelkow, E.M., Mandelkow, E. & Waldmann, H. (2007) “Rhodanine-based Tau Aggregation Inhibitors in Cell Models of Tauopathy” Angew. Chem. Int. Ed. 46, 9215-9219